Efficacy and Safety of Regofinib in the Treatment of Advanced Osteosarcoma and Soft Tissue Sarcoma:A Meta-Analysis
Objective To evaluate the efficacy and safety of regofinib in the treatment of advanced osteosarcoma and soft tissue sarcoma.Methods Randomized controlled trials(RCTs)related to regofinib in the treatment of advanced osteosarcoma and soft tissue sarcoma in the PubMed,Embase,The Cochrane Library,Web of Science,CNKI,WanFang,VIP,and CBM databases from their inception to November 19,2023 were searched.The Cochrane risk assessment scale was used to evaluate the quality of the included literature,and RevMan 5.3 software was used for Meta-analysis.Results Eight RCTs were included,involving 455 patients.Meta-analysis results showed that the disease control rate[OR=4.18,95％CI(2.59,6.75),P＜0.000 01],3-month progression-free survival(PFS)rate[OR=4.18.95％CI(2.69,6.48),P＜0.000 01],and 6-month PFS rate[OR=3.99,95％CI(2.29,6.93),P＜0.000 01]in the experimental group(treated with regofinib)were significantly higher than those in the control group(treated with placebo).The sub-group analysis results showed that the 3-month PFS rate[OR=6.22,95％CI(2.93,13.23),P＜0.000 01]and 6-month PFS rate[OR=3.62,95％CI(1.57,8.38),P=0.003]of patients with osteosarcoma in the experimental group were significantly better than those in the control group;the 3-month PFS rate[OR=6.63,95％CI(3.17,13.86),P＜0.000 01]and 6-month PFS rate[OR=6.84,95％CI(2.57,18.19),P=0.000 1]of patients with soft tissue sarcoma without liposarcoma in the experimental group were significantly higher than those in the control group.The incidence of hypertension,hand-foot skin reactions,and diarrhea,as well as the incidence of grade ≥ 3 hypertension,hand-foot skin reactions,diarrhea,and fatigue in the experimental group were significantly higher than those in the control group(P＜0.05).Conclusion Regofinib is effective in the treatment of patients with soft tissue sarcoma and osteosarcoma without liposarcoma,and the risk of adverse reactions is basically controllable.
万方数据
维普
